



Toxicological Profile for Chloroform

October 2024



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute-, intermediate-, and chronic-duration exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
October 2024	Final toxicological profile released
January 2024	Draft for public comment toxicological profile released
September 1997	Final toxicological profile released
April 1993	Final toxicological profile released
January 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, Ph.D. (Lead)
Custodio Muianga, M.P.H., Ph.D.
Mohammad Shoeb, Ph.D.

Kimberly Zaccaria, Ph.D., D.A.B.T.
Zachariah Guerrette, Ph.D., D.A.B.T.
Mario Citra, Ph.D.
Nathan Craig, Ph.D.
Deborah Herber, Ph.D.
Jessica Myers, Ph.D.
Marc Odin, Ph.D.
Savannah Sierco, M.S.
SRC, Inc., North Syracuse, NY

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. Udayan Apte, Ph.D., D.A.B.T., FAASLD; Professor, Department of Pharmacology Toxicology and Therapeutics; Associate Director, KU Liver Center; University of Kansas Medical Center; Kansas City, Kansas
2. Georg Thomas Wondrak, Ph.D.; Professor, Department of Pharmacology and Toxicology; Professor, Cancer Biology; Director of Graduate Studies, RK Coit College of Pharmacy; University of Arizona; Tucson, Arizona
3. Jerry Campbell, Ph.D.; Managing Consultant; Ramboll; Raleigh, North Carolina
4. Nick M. Filipov, Ph.D., ATS; Lalita and Raghubir Sharma Distinguished Professor in Toxicology; Director, Interdisciplinary Toxicology Program; Department of Physiology and Pharmacology; College of Veterinary Medicine; University of Georgia; Athens, Georgia; peer-review of the study by DHA (2022) only
5. Jason Cannon, Ph.D.; Acting Head and Professor of Toxicology; School of Health Sciences; Assistant Vice Provost for Interdisciplinary Graduate Programs; Purdue University; West Lafayette, Indiana; peer-review of the study by DHA (2022) only

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	iv
CONTRIBUTORS & REVIEWERS	v
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs)	8
CHAPTER 2. HEALTH EFFECTS.....	12
2.1 INTRODUCTION.....	12
2.2 DEATH	89
2.3 BODY WEIGHT.....	92
2.4 RESPIRATORY	95
2.5 CARDIOVASCULAR.....	98
2.6 GASTROINTESTINAL.....	100
2.7 HEMATOLOGICAL	101
2.8 MUSCULOSKELETAL	102
2.9 HEPATIC.....	104
2.10 RENAL	122
2.11 DERMAL.....	135
2.12 OCULAR	136
2.13 ENDOCRINE.....	137
2.14 IMMUNOLOGICAL	138
2.15 NEUROLOGICAL.....	140
2.16 REPRODUCTIVE	146
2.17 DEVELOPMENTAL.....	154
2.18 OTHER NONCANCER.....	166
2.19 CANCER.....	167
2.20 GENOTOXICITY	178
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	185
3.1 TOXICOKINETICS.....	185
3.1.1 Absorption.....	185
3.1.2 Distribution	190
3.1.3 Metabolism.....	193
3.1.4 Excretion	197
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	199
3.1.6 Animal-to-Human Extrapolations.....	214
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	215
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	217

3.3.1	Biomarkers of Exposure.....	218
3.3.2	Biomarkers of Effect.....	219
3.4	INTERACTIONS WITH OTHER CHEMICALS	220
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		224
4.1	CHEMICAL IDENTITY	224
4.2	PHYSICAL AND CHEMICAL PROPERTIES	224
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		226
5.1	OVERVIEW	226
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	229
5.2.1	Production	229
5.2.2	Import/Export.....	231
5.2.3	Use	232
5.2.4	Disposal.....	233
5.3	RELEASES TO THE ENVIRONMENT.....	233
5.3.1	Air	234
5.3.2	Water.....	238
5.3.3	Soil	239
5.4	ENVIRONMENTAL FATE	240
5.4.1	Transport and Partitioning.....	240
5.4.2	Transformation and Degradation	242
5.5	LEVELS IN THE ENVIRONMENT.....	245
5.5.1	Air	246
5.5.2	Water.....	249
5.5.3	Sediment and Soil	252
5.5.4	Other Media	253
5.6	GENERAL POPULATION EXPOSURE.....	256
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	262
CHAPTER 6. ADEQUACY OF THE DATABASE.....		265
6.1	INFORMATION ON HEALTH EFFECTS.....	265
6.2	IDENTIFICATION OF DATA NEEDS	267
6.3	ONGOING STUDIES.....	276
CHAPTER 7. REGULATIONS AND GUIDELINES		277
CHAPTER 8. REFERENCES		280
APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS		A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR CHLOROFORM		B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR CHLOROFORM.....		C-1
APPENDIX D. USER'S GUIDE.....		D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS		E-1
APPENDIX F. GLOSSARY		F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....		G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to Chloroform.....	3
1-2. Health Effects Found in Animals Following Oral Exposure to Chloroform.....	4
1-3. Summary of Sensitive Targets of Chloroform – Inhalation	9
1-4. Summary of Sensitive Targets of Chloroform – Oral.....	10
2-1. Overview of the Number of Studies Examining Chloroform Health Effects.....	16
2-2. Levels of Significant Exposure to Chloroform – Inhalation.....	35
2-3. Levels of Significant Exposure to Chloroform – Oral.....	71
3-1. Metabolic Pathways of Chloroform Biotransformation	195
3-2. Parameters Used in the Corley et al. (1990) Physiologically Based Pharmacokinetic Model	202
5-1. Number of NPL Sites with Chloroform Contamination.....	226
6-1. Summary of Existing Health Effects Studies on Chloroform by Route and Endpoint.....	266

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Chloroform	11
2-1. Levels of Significant Exposure to Chloroform – Inhalation.....	17
2-2. Levels of Significant Exposure to Chloroform – Oral.....	46
2-3. Levels of Significant Exposure to Chloroform – Dermal.....	88
2-4. Results of Epidemiological Studies Evaluating Exposure to Chloroform and Hepatic Effects	104
2-5. Non-Neoplastic Hepatic Lesions in Rats Following Inhalation Exposure to Chloroform	109
2-6. Non-Neoplastic Hepatic Lesions in Mice Following Inhalation Exposure to Chloroform	111
2-7. Non-Neoplastic Hepatic Lesions in Rats Following Gavage Exposure to Chloroform	114
2-8. Non-Neoplastic Hepatic Lesions in Mice Following Gavage Exposure to Chloroform	115
2-9. Hepatic Clinical Chemistry in Rats Following Gavage Exposure to Chloroform.....	118
2-10. Hepatic Clinical Chemistry in Mice Following Gavage Exposure to Chloroform.....	119
2-11. Results of Epidemiological Studies Evaluating Exposure to Chloroform and Renal Effects	123
2-12. Non-Neoplastic Renal Lesions in Rats Following Inhalation Exposure to Chloroform.....	125
2-13. Non-Neoplastic Renal Lesions in Mice Following Inhalation Exposure to Chloroform	126
2-14. Non-Neoplastic Renal Lesions in Rats Following Gavage Exposure to Chloroform.....	130
2-15. Non-Neoplastic Renal Lesions in Mice Following Gavage Exposure to Chloroform	131
2-16. Results of Epidemiological Studies Evaluating Exposure to Chloroform and Neurological Effects.....	142
2-17. Results of Epidemiological Studies Evaluating Exposure to Chloroform and Reproductive Effects.....	146
2-18. Results of Epidemiological Studies Evaluating Exposure to Chloroform and Developmental Effects	154
2-19. Results of Epidemiological Studies Evaluating Exposure to Chloroform and Cancer Effects	167
2-20. Genotoxicity of Chloroform <i>In Vitro</i>	178
2-21. Genotoxicity of Chloroform <i>In Vivo</i>	180
3-1. Parameters Used in the Corley et al. (1990) Physiologically Based Pharmacokinetic Model	203
4-1. Chemical Identity of Chloroform	224
4-2. Physical and Chemical Properties of Chloroform	225

5-1. Facilities that Produce, Process, or Use Chloroform	230
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Chloroform.....	234
5-3. National Emission Inventory (NEI) Total National Emissions for Chloroform Estimated by Sector, 2020	235
5-4. Lowest Limit of Detection Based on Standards	245
5-5. Summary of Environmental Levels of Chloroform	246
5-6. Chloroform Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	246
5-7. Summary of Annual Concentrations of Chloroform (ppbv) Measured in Ambient Air at Locations Across the United States	247
5-8. Summary of Concentrations of Chloroform (ppb) Measured in Surface and Groundwater Across the United States.....	250
5-9. Summary of Chloroform Measured in Food and Beverages in the United States (ppb)	254
5-10. Reasonable Maximum Exposure Daily Inhalation Dose in $\mu\text{g}/\text{kg}/\text{day}$ and Administered Dermal Dose of Chloroform for the Target Person	259
5-11. Geometric Mean and Selected Percentiles of Chloroform Blood Concentrations (pg/mL) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) (2011–2018).....	260
7-1. Regulations and Guidelines Applicable to Chloroform.....	277